Skip to main content

Table 6 Mulitvariate analysis for prediction of recurrence adjusted for results of cytology, time interval between last NMIBC and urine sampling and European Organization for Research and Treatment of Cancer (EORTC) risk groups

From: Prognostic relevance of positive urine markers in patients with negative cystoscopy during surveillance of bladder cancer

  Model 1 (Cytology) Model 2 (Cytology & FISH) Model 3 (Cytology& uCyt+) Model 4 (Cytology & NMP22)
  Hazard ratio p Hazard ratio p Hazard ratio p Hazard ratio p
Cytology 2.8 (1.2-7.0) .02 2.2 (0.8-6.3) .13 1.9 (0.7-5.1) .18 2.6 (1.0-6.5) .04
FISH   1.6 (0.6-4.6) .34   
uCyt+   3.23 (1.2-8.7) .01  
NMP22   3.1 (1.2-8.6) .01
Last tumor < vs. > 6 months 3.6 (1.5-8.9) .001 3.8 (1.6-9.6) .003 4.2 (1.7-11.0) .002 3.0 (1.2-7.9) .01
History of low/intermediate vs. high risk urothelial carcinoma 1.2 (0.5-2.9) .83 1.1 (0.5-2.7) .72 1.4 (0.5-3.5) .51 1.2 (0.5-3.2) .64
  1. FISH = Fluorescence in situ hybridization, NMP22 = Nuclear matrix protein 22, uCyt+ = Immunocytology